Drug Database
PR

pregabalin (Lyrica OD)

✓ Approved

Eisai Co., Ltd. · CACNA2D1 · 小分子

什么是 pregabalin?

pregabalin 是一种小分子,由Eisai Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Lyrica OD
公司Eisai Co., Ltd.
药物类别小分子
分子靶点CACNA2D1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

pregabalin 作用于 1 个分子靶点:

CACNA2D1calcium voltage-gated channel auxiliary subunit alpha2delta 1 (LINC01112, CACNA2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pregabalin 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersFibromyalgia✓ Approved
Nervous system disordersDiabetic neuropathyPreclinical
Nervous system disordersPost herpetic neuralgiaPreclinical

相关研究文献

PubMedParasites & vectors2026-11-19

Probiotic potential of Blautia producta L1 in mitigating Eimeria tenella-induced intestinal inflammation and dysbiosis in chickens.

Liu Jianhua J, Yuan Cheng C, Zhang Guangji G, Zhao Changjing C et al.

The capacity of Blautia to restore microbial homeostasis and attenuate intestinal inflammation highlights its potential as a promising microbial therapeutic for poultry coccidiosis. A total of 75 one-day-old male Hy-Line layer chicks were randomly allocated into five groups (n=15 per group): mock control, challenged control, B. producta L1 control, B. producta L1-challenged, and inactivated B. producta L1-challenged. From day 1 to day 22, chickens in the B. producta L1-treatment groups were orally administered either live or heat-inactivated B. producta L1 at 2 × 10⁸ CFU/mL (1 mL/bird) once daily. On day 14, chickens in the challenged groups were orally gavaged with 3 × 104 sporulated E. tenella oocysts. Protective efficacy was assessed by body weight gain, fecal oocyst out, cecal lesion score (0-4), and histopathological examination of intestinal epithelium. The anticoccidial index (ACI) was also calculated. Inflammatory cytokines including IL-1β, IL-6, TNF-α, and IL-10 were analyzed by ELISA, and mRNA expression of genes related to cecal inflammatory pathways was analyzed by qRT-PCR. The composition of the cecal microbiota was profiled using 16S rRNA gene sequencing. Supplementation with either live or heat-inactivated B. producta L1 conferred measurable protection against E. tenella challenge. Body weight gain in the live and inactivated B. producta L1-treated groups was significantly greater than that of the challenged control group (p < 0.01). Cecal lesion scores and fecal oocyst output were markedly reduced in both B. producta L1-treated groups compared with the challenged control group (p < 0.001 for both). Survival was 100% in both B. producta L1-treated groups and 86.7% (13/15) in the challenged control group. However, the between-group difference in survival was not statistically significant. The ACI values of the live and inactivated B. producta L1-treated groups were 162.0 and 151.6, respectively, corresponding to medium-effective and effective protection according to the established ACI criteria, compared with 102.2 in the challenged control group. Histopathological examination showed less epithelial degeneration, necrosis, and villus atrophy in B. producta L1-treated birds. Moreover, B. producta L1 supplementation significantly decreased serum concentrations of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α; p < 0.01) and increased the anti-inflammatory cytokine IL-10 (p < 0.05), while downregulating mRNA expression of TLR4, MYD88, NF-κB, NLRP3, P65, and Caspase-3 in cecal tissues (p < 0.05 for all). 16S rRNA gene sequencing further demonstrated that B. producta L1 increased cecal microbial richness and diversity, with higher relative abundances of beneficial genera such as Blautia and Lactobacillus and lower abundances of potentially pathogenic taxa including Salmonella, Acinetobacter, and Erysipelatoclostridium (p < 0.05). B. producta L1 moderately ameliorates E. tenella-induced pathology by helping preserve intestinal barrier integrity, dampening inflammatory responses, and reshaping the gut microbial ecosystem. These findings support B. producta L1 as a promising probiotic or postbiotic candidate for complementary control of E. tenella infection in poultry, although further benchmarking against standard anticoccidial agents and identification of active bioactive components are required.

PMID 43053077
阅读全文 →
PubMedVeterinary medicine and science2026-11-19

Cutaneous Effects of Oral Polystyrene Microplastic Exposure in Mice: Oxidative Stress, Inflammation, and FGF5 Gene Dysregulation.

Islam Md Sadequl MS, Koedrith Preeyaporn P

Microplastic (MP) pollution represents an escalating threat to mammalian health, yet the potential effects of oral MP exposure on mammalian skin remain poorly understood. This study investigated the effects of oral polystyrene microplastic (PS-MP) exposure on skin integrity, oxidative balance, and the expression of the Fibroblast Growth Factor 5 (FGF5) gene a key regulator controlling the transition between hair growth and regression phases in the hair cycle. Male Swiss albino mice were orally exposed to PS-MPs (4.8-5 µm) at low (0.1 mg) and high (0.2 mg) doses for 28 consecutive days. Biochemical analyses evaluated oxidative stress markers (CAT, SOD, POD, ROS, and MDA), serum enzyme activity (ALT, AST, ALP, and amylase), and mineral concentrations (Ca, Mg, and phosphate). Histopathological examination of H&E-stained skin sections assessed epidermal thickness, keratinocyte density, and dermal inflammation. Quantitative real-time PCR was used to measure FGF5 gene expression in dorsal skin, with Hprt1 as the internal control. Oral PS-MP exposure was associated with dose-dependent oxidative stress in skin tissue, reflected by elevated ROS (0.545 → 1.99 U/mg) and MDA (1.49 → 7.37 nmol/L) levels and significant depletion of antioxidant enzymes such as CAT (10.2 → 4.33 U/mg protein). Serum biochemical disturbances confirmed systemic metabolic stress. Histopathology revealed epidermal hyperplasia (16.46 → 34.18 µm), reduced keratinocyte density (22.1 → 7.0), and marked inflammatory infiltration. Importantly, FGF5 expression increased 1.35-fold, suggesting altered regulation of pathways associated with hair-follicle cycling. Oral PS-MP exposure was associated with oxidative stress, structural alterations, inflammation, and FGF5 upregulation in mouse skin. These findings suggest a potential association between oral PS-MP exposure and disruption of skin and hair-follicle homeostasis in mammals.

PMID 43052231
阅读全文 →
PubMedRehabilitacion2026-11-18

[Clinical profile and management of patients with neuropathic pain treated with pregabalin in rehabilitation clinics in Spain: the PRELURE cross-sectional survey].

de Miguel Benadiba C C, Ambrós Helena Bascuñana HB

To describe the clinical profile and management of patients with neuropathic pain referred for the first time to Physical Medicine and Rehabilitation clinics in Spain, as well as the use of pregabalin. A descriptive, nationwide survey based on aggregated data obtained through an online questionnaire. Each participant provided information on their last 6 patients with neuropathic pain referred for the first time and prescribed pregabalin at the consultation. A total of 124 specialists participated. Among their patients, chronic pain predominated (100.0%; Q1-Q3: 66.7-100.0), with a median duration of 8 months, as did mixed neuropathic-nociceptive pain (66.7%; Q1-Q3: 33.3-100.0). Baseline pain intensity (0-10) was high, with a mean score of 7.2 (SD 1.2) in women and 6.8 (SD 1.0) in men. Functional impairment, sleep and mood impairment were frequent. Before referral, pregabalin use was limited, with a mean initial dose of 104.9 (SD 65.7) mg/day in women and 130.5 (SD 110.8) mg/day in men. Following the consultation, the reported mean dose was 147.4 (SD 112.2) and 148.8 (SD 92.4) mg/day, respectively. Based on the physicians' retrospective estimates, at three months after treatmen adjustment, they perceived a reduction in the mean proportion of patients experiencing severe pain to 5.9% in women and 4.8% in men. Patients referred to Rehabilitation and treated with pregabalin present a high symptomatic and functional burden. Lower doses were observed before referral. After the consultation, treatment was adjusted and physicians perceived a reduction in patients with severe pain at three months.

PMID 43051522
阅读全文 →
PubMedAnalytical chemistry2026-11-18

MALDI-TOF Mass Spectrometry Imaging for Spatially Resolved Degradation Profiling of Solid Formulations.

Thomas Rekha R, Vargas Karina A KA, Shi Zhenqi Z, Gruenhagen Jason J et al.

Understanding the stability of the active pharmaceutical ingredient (API) and drug-excipient interactions is critical for ensuring the efficacy and shelf life of pharmaceutical formulations. This study applies matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to investigate two-dimensional (2D) and three-dimensional (3D) spatial profiling of degradants in Losartan potassium tablets that are subjected to temperature- and humidity-induced stress conditions. This approach allows for in situ visualization of API degradation and excipient compatibility within solid dosage forms. Upon stress, Losartan tablets formed dimeric and trimeric species as major degradation products. Spatial mapping revealed a gradual growth of these degradants from the control (T0) through four weeks of stress. Ion images showed distinct heterogeneity in the formation of dimer and trimer species across the tablet depth and plane; however, no preferential pattern was observed at the tablet periphery. The random distribution of degradants suggests that alongside humidity, localized microenvironments drive the degradation process. MALDI-MSI demonstrates strong potential as a high-throughput and sensitive alternative to traditional liquid chromatography-based procedures for early-stage formulation screening. Furthermore, this work suggests that when integrated with orthogonal techniques to coregister excipient domains, MALDI-MSI can serve as an emerging tool to uniquely characterize drug-excipient interactions during early-stage drug development. This provides spatially resolved insight that enhances accelerated stability assessment programs and streamline the selection of compatible excipients.

PMID 43046425
阅读全文 →
PubMedFrontiers in human neuroscience2026-11-18

A thalamus-centered network model of restless legs syndrome: an integrative hypothesis illustrated by three clinical phenotypes.

Vághy Beatrix B, Komoly Sámuel S, Várbíró Szabolcs S

Restless legs syndrome (RLS) is a clinically heterogeneous sensorimotor disorder whose pathophysiology reflects interacting biological mechanisms rather than a single causal pathway. Established influences-including brain iron biology, dopaminergic regulation, glutamatergic and GABAergic balance, adenosinergic inhibition, and abnormal afferent processing-have typically been studied in isolation, leaving their systems-level relationships insufficiently integrated. To motivate a network-based interpretation, we present three illustrative clinical phenotypes: dopamine-agonist augmentation, sensory-predominant RLS with inadequate response to pregabalin, and persistent symptoms despite partial correction of peripheral iron deficiency. These cases highlight how distinct upstream contexts can converge on similar sensory and sleep-physiological endpoints. Human neuroimaging and neurochemical studies provide convergent evidence for thalamic involvement in RLS, including altered thalamic connectivity, differences in thalamic nuclei and network organization, and increased thalamic glutamate/glutamine signal associated with disturbed sleep. Because the thalamus integrates sensory gating, motor modulation, arousal regulation, and sleep-wake stability, it represents a plausible convergence hub for upstream biological influences. We therefore propose a thalamus-centered convergence model in which iron deficiency, dopaminergic instability, glutamatergic hyperresponsiveness, reduced adenosinergic inhibition, altered GABAergic modulation, and abnormal afferent processing interact to increase the susceptibility of thalamo-cortical networks to sensory and arousal instability. The model does not replace established frameworks; instead, it organizes them within a unified, testable network architecture. We outline six falsifiable predictions for multimodal imaging, sleep microstructure, sensory physiology, and treatment-response studies, providing a structured basis for future mechanistic investigation of RLS.

PMID 43048388
阅读全文 →
PubMedEpilepsia2026-11-18

Validation of drug-resistant epilepsy identification algorithms in US Veterans across diverse care settings.

Haneef Zulfi Z, Nagabhirava Rohan S RS, Hildebrand Andrea D AD, Zhou Richard R et al.

Early recognition of drug-resistant epilepsy (DRE) is critical for timely referral to comprehensive epilepsy centers (CECs). Our prior pilot study in the Veterans Health Administration (VHA) demonstrated the feasibility of an algorithm-based approach to identify DRE within selected CECs. In this study, we validated and refined these algorithms in a broader, national cohort, including CEC and non-CEC care, to optimize algorithms for different care settings. We conducted a multicenter, retrospective study of randomly sampled veterans with epilepsy on ≥2 antiseizure medications (ASMs) from 1999 to 2024. Chart review by 26 epilepsy providers rated DRE status. Ninety-six candidate algorithms using combinations of six criteria-number of ASMs, treatment duration, dose thresholds, pregabalin exclusion, intractable International Classification of Diseases (ICD) codes, and electroencephalography (EEG)/magnetic resonance imaging (MRI) utilization-were evaluated. Performance for DRE classification was evaluated among all veterans, and separately for CEC or non-CEC care. Among 970 veterans on ≥2 lifetime ASMs, 518 (53.4%) were rated as DRE, 363 (37.4%) as non-DRE, and 89 (9.2%) as undetermined. Veterans with DRE were younger (mean age = 68.9 vs. 72.0 years) and more frequently had at least one intractable ICD code (46.1% vs. 18.2%), EEG (77.8% vs. 66.7%), or MRI (78.0% vs. 65.8%) compared with non-DRE (all p-values <.001). Among all veterans, the best overall algorithm (area under the curve [AUC] = .701) identified DRE as either (1) exposure to 3+ ASMs or (2) exposure to two ASMs for at least 1 year, with the requirement of past EEG/MRI and intractable ICD code documentation. This algorithm was also highly effective among veterans who received CEC (AUC = .756) or only non-CEC care (AUC = .678). This national validation study confirms that medication-based algorithms can identify DRE within VHA administrative data across care settings (CECs and non-CECs). This supports the implementation of a standardized DRE definition for quality improvement, surveillance, and referral optimization within the VHA.

PMID 43049542
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多pregabalin